Viridian Therapeutics (NASDAQ:VRDN - Free Report) had its price target lowered by HC Wainwright from $37.00 to $27.00 in a report released on Thursday, Benzinga reports. The firm currently has a buy rating on the stock.
A number of other research firms also recently commented on VRDN. LADENBURG THALM/SH SH downgraded shares of Viridian Therapeutics from a buy rating to a neutral rating in a report on Thursday. B. Riley downgraded shares of Viridian Therapeutics from a buy rating to a neutral rating and cut their price target for the stock from $25.00 to $20.00 in a report on Thursday. Needham & Company LLC restated a buy rating and set a $30.00 price target on shares of Viridian Therapeutics in a report on Thursday. Oppenheimer cut their price target on shares of Viridian Therapeutics from $36.00 to $31.00 and set an outperform rating for the company in a report on Thursday. Finally, Wedbush raised their price target on shares of Viridian Therapeutics from $39.00 to $40.00 and gave the stock an outperform rating in a report on Wednesday, February 28th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $34.60.
Check Out Our Latest Stock Analysis on VRDN
Viridian Therapeutics Price Performance
VRDN stock traded down $0.99 during mid-day trading on Thursday, reaching $13.91. The company's stock had a trading volume of 1,729,471 shares, compared to its average volume of 927,377. The stock has a market cap of $887.74 million, a PE ratio of -2.61 and a beta of 1.14. The company has a current ratio of 18.26, a quick ratio of 18.26 and a debt-to-equity ratio of 0.09. Viridian Therapeutics has a fifty-two week low of $10.93 and a fifty-two week high of $28.35. The company's 50 day moving average is $16.46 and its two-hundred day moving average is $17.64.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.79) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.28. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.09 million. Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. Viridian Therapeutics's quarterly revenue was down 26.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.61) EPS. Equities research analysts expect that Viridian Therapeutics will post -4.39 EPS for the current year.
Hedge Funds Weigh In On Viridian Therapeutics
A number of hedge funds have recently made changes to their positions in VRDN. Swiss National Bank grew its stake in shares of Viridian Therapeutics by 1.2% in the fourth quarter. Swiss National Bank now owns 67,200 shares of the company's stock worth $1,464,000 after acquiring an additional 800 shares in the last quarter. Knights of Columbus Asset Advisors LLC grew its stake in shares of Viridian Therapeutics by 2.9% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 29,553 shares of the company's stock worth $453,000 after acquiring an additional 823 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Viridian Therapeutics by 9.7% in the first quarter. Principal Financial Group Inc. now owns 11,915 shares of the company's stock worth $209,000 after acquiring an additional 1,058 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Viridian Therapeutics by 4.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company's stock worth $505,000 after acquiring an additional 1,135 shares in the last quarter. Finally, New York State Common Retirement Fund grew its stake in shares of Viridian Therapeutics by 9.7% in the fourth quarter. New York State Common Retirement Fund now owns 17,495 shares of the company's stock worth $378,000 after acquiring an additional 1,545 shares in the last quarter.
Viridian Therapeutics Company Profile
(
Get Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Recommended Stories
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
